Brief: Theratechnologies Inc Confirms Bioequivalence Of New Tesamorelin Formulation
July 7 (Reuters) - Theratechnologies Inc TH.TO :
* THERATECHNOLOGIES INC - CONFIRMS BIOEQUIVALENCE OF NEW
TESAMORELIN FORMULATION
* THERATECHNOLOGIES INC - SBLA EXPECTED TO BE FILED IN EARLY
2022
Source text for Eikon: ID:nGNX6mpPZH
Further company coverage: TH.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theratechnologies
See all newsBrief: Theratechnologies Receives Final Court Approval On To Be Acquired By Future Pak
Brief: Theratechnologies Inc - Iss And Glass Lewis Recommend Voting 'For' Future Pak Arrangement
Canadian drugmaker Theratechnologies beats Q2 revenue estimates on strong demand
Brief: Theratechnologies Enters Into Definitive Agreement To Be Acquired By Cb Biotechnology, An Affiliate Of Future Pak
Brief: Theratechnologies Inc Decided To Further Evaluate Potential Sale Of Company Through An Open And Non-Exclusive Process